This is the first of a 3 part series of talk on high risk smoldering myeloma and its treatments. Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. There have been major advances in the diagnosis, prognosis, and management of SMM in the last few years. High risk SMM patients carry a high risk to progression to multiple myeloma. High risk SMM has been recognised as the optimal phase to test early treatment strategies. The upcoming ASCENT trial aims to prevent progression to active myeloma by 30-50% in the high risk to progression SMM patients. We are talking to Dr. Shaji Kumar Principal Investigator of the trial and Mayo Clinic expert about the nuances of the ASCENT trial.
Dr. Shaji K Kumar is Professor of Medicine at the Mayo Clinic College of Medicine and a consultant, Mayo Clinic Division of Hematology. Dr. Kumar is board certified in medical oncology and hematology. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association of Clinical Research, American Society of Blood and Marrow Transplantation, American Medical Association, Association of Physicians of India, and the European Hematology Association. His laboratory focuses on development of novel drugs for treatment of myeloma and he has been published in numerous peer-reviewed journals including British Journal of Haematology, Blood, American Journal of Hematology, and Bone Marrow Transplant on this topic.
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register